We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

3D Hydrogel Biochips Help Detect Bowel Cancer

By HospiMedica International staff writers
Posted on 06 Jun 2016
A novel three-dimensional (3D) hydrogel-based biochip containing molecular probes can help detect serological signatures in the sera of colorectal cancer (CC) patients.

Developed by researchers at the Moscow Institute of Physics and Technology (MIPT; Russia), the Engelhardt Institute of Molecular Biology (EIMB; Moscow, Russia), and a number of other Russian research centers, the glycochip contains an array of hemispherical hydrogel cells containing immobilized proteins and oligosaccharides that can help detect tumor-associated glycans.

Image: The hydrogel-based biochip to help detect bowel cancer (Photo courtesy of MIPT.)
Image: The hydrogel-based biochip to help detect bowel cancer (Photo courtesy of MIPT.)

Besides detecting a range of antibodies against glycans (SiaTn, Tn, TF, LeC, LeY, SiaLeA, and Manβ1-4GlcNAcβ), the glycochip also contains antibodies against human immunoglobulins (IgG, IgA, and IgM). The simultaneous measurement of the levels of immunoglobulins in sera enhances the diagnostic impact of the signatures. To test the glycochips, the researchers studied 69 sera samples from healthy donors, 33 from patients with CC, and 27 from patients with inflammatory bowel diseases.

The results showed that the positive predictive value of the test system, based on the diagnostic signatures, allowed it to diagnose CC in 95% of the cases, compared to around 79% detected by traditional methods. The sensitivity of detection (in patients with Stage II-IV CC) was 87%, compared to just 21% by traditional methods. The specificity of the method was 97%. The study was published on March 19, 2016, in Cancer Medicine.

“The method developed at EIMB RAS has great potential to be used in diagnosing gastrointestinal diseases,” said study co-author Zhanna Zubtsova, PhD, an assistant professor in the physics department at MIPT. “We hope that testing systems based on the method will soon appear in clinical laboratories in Russia.”

Glycans are biopolymers consisting of a large number of monosaccharides linked by oxygen atoms. Besides acting as nutrients and building materials for cells, glycans are important for the contact between cells, appropriate organ growth, and much more. Tumor cells hold special glycans that help differentiate them from healthy cells, a key aspect of the new study.

Related Links:
Moscow Institute of Physics and Technology
Engelhardt Institute of Molecular Biology

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Multilevel Self-Loading Stretcher
CARRERA XL

Latest Critical Care News

Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time

Wearable Multiplex Biosensors Could Revolutionize COPD Management

New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias